294856-01-2

A number of 17-phenyl trinor prostaglandin F_2α (17-phenyl trinor PGF_2α) derivatives have been approved for the treatment of glaucoma. Of these, the ones wherein the 13,14-double bond has been hydrogenated retain relatively good potency, but show a significantly reduced incidence of local irritant side effects. 17-trifluoromethylphenyl-13,14-dihydro trinor PGF_2α bears an aromatic ring which is reminiscent of the trifluoromethyl-phenoxy ring of travoprost ((+)-fluprostenol isopropyl ester). As an ocular hypotensive agent, it would be expected that 17-trifluoromethylphenyl-13,14-dihydro trinor PGF_2α would act very much like the free acid of latanoprost.

17-Trifluoromethylphenyl-13,14-dihydro trinor Prostaglandin F2α is a derivative of Bimatoprost acid (HY-125774)[1].

[1] De Souza, F.I., Zumiotti, A.V., and Da Silva, C.F. Neuregulins 1-α and 1-β on the regeneration the peripheral nerves[J]. Acta Ortop Bras.
[2] Travoprost[J]. Reactions Weekly, 2009, 22 1: 40-41. DOI: 10.2165/00128415-200912530-00134
[3] BAHRAM RESUL. Phenyl-substituted prostaglandins: potent and selective antiglaucoma agents[J]. Journal of Medicinal Chemistry, 1993, 36 2: 243-248. DOI: 10.1021/jm00054a008